Does Rallies show 13F holders for XTNT?

Yes. Rallies tracks hedge fund and 13F ownership data for XTNT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XTNT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XTNT. It does not provide personalized investment advice.

XTNT (Xtant Medical Holdings, Inc.) Stock Analysis - Hedge Fund Holdings

Xtant Medical Holdings, Inc. (XTNT) is a publicly traded Healthcare sector company. As of May 21, 2026, XTNT trades at $0.46 with a market cap of $63.96M and a P/E ratio of 11.70. XTNT moved +1.33% today. Year to date, XTNT is -34.49%; over the trailing twelve months it is -33.75%. Its 52-week range spans $0.33 to $0.95. Analyst consensus is strong buy with an average price target of $1.25. Rallies surfaces XTNT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XTNT stock?

Hedge funds tracked by Rallies that own XTNT include Orbimed Advisors. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xtant Medical Holdings, Inc..

XTNT Key Metrics

Key financial metrics for XTNT
Metric	Value
Price	$0.46
Market Cap	$63.96M
P/E Ratio	11.70
EPS	$0.04
Dividend Yield	0.00%
52-Week High	$0.95
52-Week Low	$0.33
Volume	212
Avg Volume	0
Revenue (TTM)	$133.93M
Net Income	$4.97M
Gross Margin	62.92%

Top Hedge Funds Holding XTNT

Orbimed Advisors holds 73.11M shares of XTNT, changed +0.00% as of Mar 31, 2025.

Latest XTNT News

Xtant Medical Lifts 2026 Revenue Guidance to $101–$105M, Secures HEMOBLAST Distribution — May 13, 2026
Xtant Medical Launches Pre-Shaped Boat and Strip Trivium Grafts Nationwide — May 6, 2026
Xtant Medical’s 2025 Revenue Grows 14% to $133.9M, Net Income of $5M — Mar 31, 2026
Xtant Medical Finalizes $21.4M Spine Business Sale with $10.7M Payment — Mar 2, 2026

Recent XTNT Insider Trades

ORBIMED ADVISORS LLC sold 56.00M (~$23.52M) on Apr 10, 2025.
ORBIMED ADVISORS LLC sold 17.11M (~$7.19M) on Apr 10, 2025.
Brandt Kevin D bought 41.67K (~$49.84K) on Nov 17, 2023.

XTNT Analyst Consensus

3 analysts cover XTNT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1.25.

Common questions about XTNT

Who owns XTNT stock?: Hedge funds tracked by Rallies that own XTNT include Orbimed Advisors. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xtant Medical Holdings, Inc..
Does Rallies show 13F holders for XTNT?: Yes. Rallies tracks hedge fund and 13F ownership data for XTNT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XTNT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XTNT. It does not provide personalized investment advice.